1252640-75-7

Usage

Uses

Used in Pharmaceutical Industry:
(2S,4S)-1-tert-butyl 2-methyl 4-(methylthio)pyrrolidine-1,2-dicarboxylate is used as a prodrug or a building block in the development of pharmaceutical compounds due to its dicarboxylate functional group and unique stereochemistry. This allows for the creation of new drugs with specific biological activities and interactions with target molecules in the body.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (2S,4S)-1-tert-butyl 2-methyl 4-(methylthio)pyrrolidine-1,2-dicarboxylate serves as a valuable compound for studying the structure-activity relationships of potential drug candidates. Its unique molecular structure and stereochemistry enable researchers to investigate its interactions with biological targets and optimize its therapeutic properties.
Used in Drug Design and Development:
(2S,4S)-1-tert-butyl 2-methyl 4-(methylthio)pyrrolidine-1,2-dicarboxylate is utilized in drug design and development processes to create novel therapeutic agents with improved efficacy and selectivity. Its complex molecular structure and functional groups provide a foundation for the design of drugs targeting specific diseases or conditions, potentially leading to more effective treatments.

Upstream product

• 84520-67-2 (2S,4R)-4-(methylsulfonyloxy)pyrrolidine-1,2-dicarboxylic acid 1-tert-butylester-2-methylester 
• 5188-07-8 sodium thiomethoxide 
• 74844-91-0 1-tert-butyl 2-methyl (2S,4R)-4-hydroxy-1,2-pyrrolidinedicarboxylate 

Downstream Products

• 188109-89-9 (2S,4S)-4-methylsulfanyl-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 
• 1373164-85-2 (2S,4S)-tert-butyl 2-(5-(4-bromophenyl)-1H-imidazol-2-yl)-4-(methylthio)pyrrolidine-1-carboxylate 

Relevant academic research and scientific papers

TRI-SUBSTITUTED HETEROARYL DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS

The present disclosure provides certain tri-substituted heteroaryl derivatives that are Src Homology-2 phosphatase (SHP2) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of SHP2. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Compounds for inhibiting HCV (hepatitis C virus), pharmaceutical composition and application of compounds or pharmaceutical composition

The invention discloses compounds for inhibiting HCV (hepatitis C virus), pharmaceutical composition and an application of the compounds or the pharmaceutical composition. The compounds are compoundsshown in formula (I) or a stereoisomer, geometric isomer, a tautomer, an enantiomer, sulfur oxide, nitrogen oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug of the compounds shown in formula (I); the compounds are effective antiviral drugs, especially can be used for inhibiting the function of NS5A protein encoded by the HCV, thereby effectively inhibiting the HCV.The method for preventing and/or treating drugs or diseases associated with the HCV by the compounds or the composition containing the new compounds has good market development prospects.

POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS

The present invention is directed to compounds, compositions and methods for treating or preventing hepatitis C virus (HCV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and othe